Evidence map›Paper›PMID 40151684›Full record

ArticleCureus2025

Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia.

Kevin T Dao, Carlos D'Assumpcao, Rupam Sharma, Chandpreet Singh, Rasha Kuran, Arash Heidari

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kevin T DaoInternal Medicine, UCLA-Kern Medical, Bakersfield, USA.
Carlos D'AssumpcaoInfectious Diseases, UCLA-Kern Medical, Bakersfield, USA.
Rupam SharmaInternal Medicine, UCLA-Kern Medical, Bakersfield, USA.
Chandpreet SinghInternal Medicine, UCLA-Kern Medical, Bakersfield, USA.
Rasha KuranInfectious Diseases, UCLA-Kern Medical, Bakersfield, USA.
Arash HeidariInternal Medicine, UCLA-Kern Medical, Bakersfield, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Telavancin is a fairly novel antibiotic derived from vancomycin developed to combat the constant evolutionary war against bacteria. It has achieved high clinical success in its role in treating Gram-positive organisms, although like in the case of any other antibiotics, failure can arise. The purpose of this article is to describe a case in which telavancin clinically failed in treating persistent methicillin-resistant

Indexed as

antibiotic resistancecross-reactivityevolutionimmunocompromisedtelavancinvancomycin derivative

Identifiers

PMID40151684
PMCPMC11948889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.